Regeneron gets FDA nod for squamous cell carcinoma therapy

[Cancer cells]

* Regeneron Pharmaceuticals (NASDAQ:REGN [https://seekingalpha.com/symbol/REGN]) has received approval from the U.S. FDA for its monoclonal antibody, Libtayo (cemiplimab), as an additional treatment for patients with cutaneous squamous cell carcinoma.
* The company has also submitted a regulatory application in the European Union for Libtayo, with a decision anticipated by mid-2026.
* The FDA's approval [https://seekingalpha.com/pr/20259597-libtayo-cemiplimab-rwlc-approved-in-the-u-s-as-first-and-only-immunotherapy-for-adjuvant]is supported by data from the phase 3 C-POST trial, which indicated that Libtayo can reduce the risk of cancer recurrence or death by 68% compared to a placebo.

MORE ON REGENERON PHARMACEUTICALS

* Regeneron: Growth Catalysts Incoming [https://seekingalpha.com/article/4827026-regeneron-growth-catalysts-incoming]
* Regeneron: Strong R&D Pipeline Drives Growth Outlook [https://seekingalpha.com/article/4826353-regeneron-strong-r-and-d-pipeline-drives-growth-outlook]
* Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript [https://seekingalpha.com/article/4825561-regeneron-pharmaceuticals-inc-regn-presents-at-bernstein-insights-healthcare-leaders-and]
* Regeneron says $83M acquired IPR&D charge to negatively hit Q3 income [https://seekingalpha.com/news/4501943-regeneron-says-83m-acquired-iprd-charge-to-negatively-hit-q3-income]
* FDA won't accept new drug applications during government shutdown [https://seekingalpha.com/news/4500750-fda-wont-accept-new-drug-applications-during-government-shutdown]